emtricitabine and tenofovir disoproxil fumarate tablet, film coated
pharmasource meds, llc - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine and tenofovir disoproxil fumarate tablets are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 17 kg [see clinical studies ( 14)]. emtricitabine and tenofovir disoproxil fumarate tablets are indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection. individuals must have a negative hiv-1 test immediately prior to initiating emtricitabine and tenofovir disoproxil fumarate tablets for hiv-1 prep [see dosage and administration ( 2.2), warnings and precautions ( 5.2)]. emtricitabine and tenofovir disoproxil fumarate tablets for hiv-1 prep is contraindicated in individuals with unknown or positive hiv-1 status [ see warnings and precautions ( 5.2)]. pregnancy exposure registry there is a
emtricitabine and tenofovir disoproxil fumarate tablet, film coated
proficient rx lp - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine and tenofovir disoproxil fumarate tablets are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 17 kg [see clinical studies (14)] . emtricitabine and tenofovir disoproxil fumarate tablets are indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection. individuals must have a negative hiv-1 test immediately prior to initiating emtricitabine and tenofovir disoproxil fumarate tablets for hiv-1 prep [see dosage and administration (2.2), warnings and precautions (5.2)] . emtricitabine and tenofovir disoproxil fumarate tablets for hiv-1 prep is contraindicated in individuals with unknown or positive hiv-1 status [see warnings and precautions (5.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to emtricitabine and tenofovir disoproxil
emtricitabine and tenofovir alafenamide tablets film-coated tablet
hetero labs limited 7-2-a2, hetero corporate, industrial estates, - emtricitabine and tenofovir alafenamide - film-coated tablet - emtricitabine and tenofovir alafenamide tablets - emtricitabine and tenofovir alafenamide
emtricitabine/tenofovir alafenamide tablets 200 film-coated tablet
mylan laboratories limited plot no.564/a/22, road no.92, jubilee hills, - emtricitabine/ tenofovir alafenamide fumarate - film-coated tablet - emtricitabine 200 mg/tenofovir alafenamide - emtricitabine and tenofovir alafenamide
emtricitabine 200mg tenofovir 245mg tablets
zentiva - tenofovir disoproxil fumarate; emtricitabine - tablet - 245mg ; 200mg
emtricitabine 200mg tenofovir 245mg tablets
lupin healthcare (uk - tenofovir disoproxil fumarate; emtricitabine - tablet - 245mg ; 200mg
emtricitabine 200mg tenofovir 245mg tablets
dr reddy's laboratories (uk - tenofovir disoproxil fumarate; emtricitabine - tablet - 245mg ; 200mg
riva-tenofovir tablet
laboratoire riva inc. - tenofovir disoproxil fumarate - tablet - 300mg - tenofovir disoproxil fumarate 300mg - nucleoside and nucleotide reverse transcriptase inhibitors
complera- emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate tablet, film coated
a-s medication solutions - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), rilpivirine hydrochloride (unii: 212wax8kdd) (rilpivirine - unii:fi96a8x663), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine 200 mg - complera® , a combination of two nucleoside analog hiv-1 reverse transcriptase inhibitors (nrtis) (emtricitabine and tenofovir disoproxil fumarate) and one non-nucleoside reverse transcriptase inhibitor (nnrti) (rilpivirine), is indicated for use as a complete regimen for the treatment of hiv-1 infection in patients 12 years of age and older with no antiretroviral treatment history and with hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy, and in certain virologically-suppressed (hiv-1 rna <50 copies/ml) patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see below). - the following points should be considered when initiating therapy with complera in patients with no antiretroviral treatment history: more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure (hiv-1 rna ≥50 copies/ml) compared
emtricitabine/tenofovir disoproxil mylan
mylan pharmaceuticals limited - emtricitabine, tenofovir disoproxil maleate - hiv infections - antivirals for systemic use - treatment of hiv-1 infection:emtricitabine/tenofovir disoproxil mylan is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults (see section 5.1).emtricitabine/tenofovir disoproxil mylan is also indicated for the treatment of hiv-1 infected adolescents, with nrti resistance or toxicities precluding the use of first line agents, (see sections 4.2, 4.4 and 5.1).pre-exposure prophylaxis (prep):emtricitabine/tenofovir disoproxil mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults and adolescents at high risk (see sections 4.2, 4.4 and 5.1).